Ones To Watch News
Refine Search
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Biotechnology
Shares of Dutch immunology specialist argenx slumped as much as 30% to 290.60 euros this morning, after it announced disappointing top-line results from the ADDRESS study 20 December 2023
Biotechnology
Danish gene expert Hervolution Therapeutics has appointed J Robert Coleman as chief executive. 20 December 2023
Biotechnology
Shares of Israel-based clinical-stage cancer immunotherapy company Compugen leapt as much as a massive 184% to $2.07 on the news of a licensing deal. 19 December 2023
Biotechnology
Avacta Group, a UK life sciences company developing innovative, targeted oncology drugs and diagnostics, has appointed Simon Bennett as chief business officer of the therapeutics division. 19 December 2023
Pharmaceutical
Hoping to capitalize on a tsunami of interest in GLP-1 agonists for weight loss, Structure Therapeutics has now published Phase IIa data for its oral candidate, but investors are not happy. 19 December 2023
Biotechnology
The European Commission has extended the approval of Evkeeza (evinacumab) as an adjunct to diet and other lipid-lowering therapies to treat children aged five to 11 years with homozygous familial hypercholesterolemia (HoFH). 19 December 2023
Biotechnology
US biotech bluebird bio saw a negative reaction to its proposed sales of shares, with the stock closing down 6.7% and a further15.6% to $2.575 in after-hours trading on Monday. 19 December 2023
Pharmaceutical
Rain Oncology is to be acquired by Pathos AI for $1.16 per share, a 17% premium on the former firm’s share price. 18 December 2023
Pharmaceutical
Vicore Pharma, a Swedish pharma company seeking to unlock the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), has announced that Bertil Lindmark will join as chief medical officer. 18 December 2023
Biotechnology
Shares of Blue Water Biotech were down 11.8% at $0.24 pre-market, after it announced the acquisition of Proteomedix. 18 December 2023
Biotechnology
Australian biotech Neuren Pharmaceuticals saw its share jump more than 22% to A$29.5 today, after it announced top-line results from its Phase II clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS). 18 December 2023
Biotechnology
French immuno-oncology company Innate Pharma has announced the resignation of chief executive Mondher Mahjoubi. 18 December 2023
Biotechnology
US provider of chemical biology technologies Totus Medicines has announced the appointment of Nassim Usman as president and chief executive. 16 December 2023
Biotechnology
Cambridge, UK-based biotech Bicycle Therapeutics has hosted its first R&D day for investors and analysts, in New York. 15 December 2023
Biotechnology
Antibody specialist Nona Biosciences, a wholly-owned subsidiary of Hong Kong-based HBM Holdings, has entered into an exclusive license agreement with Pfizer. 15 December 2023
Pharmaceutical
Shares in Glaukos Corporation closed more than 25% higher on Thursday. 15 December 2023
Pharmaceutical
Shares in Californian rare disease company Reneo Pharmaceuticals have plummeted after the firm announced the failure of its pivotal STRIDE study. 15 December 2023
Pharmaceutical
New York-based neurology specialist Mind Medicine has announced positive topline results from its Phase IIb clinical trial of MM-120. 14 December 2023
Biotechnology
US biotech companies Biogen and Sage Therapeutics have announced that Zurvuvae (zuranolone) is now available by prescription for the treatment of postpartum depression (PPD) for adults in the USA. 14 December 2023
Biotechnology
Allergy Therapeutics saw its share jump more than 8% to 2.10 pence by early afternoon as it released new data on its allergy candidate. 13 December 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze